Emrelis

Adults with locally advanced or metastatic nonsquamous NSCLC with high c-Met protein overexpression who have received prior systemic therapy.

1.9 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.

Injection: 340 mg lyophilized powder in single-dose vial

None listed in the prescribing information.

• Ocular Toxicity: Conduct ophthalmic exams at baseline and regularly during treatment.
• Peripheral Neuropathy: Monitor; consider dose delay, reduction, or discontinuation.
• ILD/Pneumonitis: Fatal cases reported. Monitor and permanently discontinue if confirmed.
• Embryo-Fetal Toxicity: Can cause fetal harm.

Peripheral Neuropathy (42%), Ocular Toxicity (40%), Nausea (36%), Fatigue (32%), Musculoskeletal Pain (26%), Decreased Appetite (24%), Peripheral Edema (20%), Alopecia (18%)

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

Strong CYP3A4 Inhibitors: Monitor for increased adverse reactions from the MMAE component.

Consult the full prescribing information for pregnancy-related considerations.

Refer to prescribing information for lactation guidance.

Pediatric safety and efficacy information is detailed in the full label.

Dose modifications for organ impairment are specified in the complete prescribing information.

Telisotuzumab vedotin is an ADC comprising a c-Met-directed monoclonal antibody conjugated to MMAE. Upon binding c-Met on tumor cells, it is internalized and releases MMAE, disrupting microtubules and inducing apoptosis.

Half-life (ADC): ~3-4 days. Half-life (MMAE): ~3 days. Clearance: 0.7 L/day.

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

• TELISO-V — Telisotuzumab vedotin in c-Met+ NSCLC. Phase II, n=188.
  🔬 NCT03539536 ↗

Emrelis has FDA-approved indications across the following cancer types covered on CancerDrugEvidence: